Dean Rudge
Deputy Editor
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
What’s Next? Five Things To Look Out For In December
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
Lupin Looks To Be First Out Of The Blocks On US Ingrezza, With Zydus Second
ANDA sponsors targeting Neurocrine Biosciences’ Ingrezza (valbenazine) blockbuster are in position to launch – albeit with a 14-year wait that validates the strength of the originator’s IP.
Turkey’s Abdi İbrahim Allies With mAbxience For ‘Unprecedented’ Technology Transfer
Five years after striking a biosimilars alliance with Iceland’s Alvotech, Turkish firm Abdi İbrahim – which boasts the country’s “largest biotech pharmaceutical manufacturing facility” – has shaken hands with Spanish developer mAbxience for technology transfer of an undisclosed oncology biosimilar.
Former Taro Exec Aprahamian Set To Walk Away From Price-Fixing Charges
The US federal government insisted that it was not against public interest to dismiss an indictment against the former Taro executive Ara Aprahamian, following near four-year-old charges for conspiracy to fix generic prices.
Sandoz Opens Two European Sites, In Biosimilars And Antibiotics
Newly separated Sandoz has provided a trio of updates, foremost for its manufacturing and research ambitions for both biosimilars and antibiotics.